IP Library Granted Patent US 9,642,845
Granted Patent B2
US 9,642,845 · App. 12/449,793 · Granted May 9, 2017

Method for alleviating side effects of retinoic acid therapy and/or improving efficacy without interfering with efficacy

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,642,845
App. No.
12/449,793
Granted
May 9, 2017
Kind
B2
Abstract

The invention relates to the use of nicotinic acid alkyl esters, especially myristyl nicotinate, to inhibit side effects associated with retinoic acid therapy. Also a part of the invention is a method for improving skin cell differentiation by administering the nicotinic acid alkyl ester in an amount sufficient to increase expression of caspase 14 and filaggrin. Deficiencies in expression of these molecules can be treated in this way as well.

Claims (7)

1. A method for alleviating or preventing a side effect caused by retinoic acid without interfering with efficacy of said retinoic acid, comprising administering an amount of a nicotinic acid alkyl ester selected from the group consisting of myristyl nicotinate and palmityl nicotinate sufficient to alleviate or to prevent said side effect, to a subject for at least one month prior to said subject receiving, or while said subject is receiving, said retinoic acid.

2. The method of claim 1 wherein said nicotinic acid alkyl ester is administered topically.

3. The method of claim 1 , wherein said nicotinic acid alkyl ester is administered by dermal or transdermal delivery.

4. The method of claim 1 , comprising administering said nicotinic acid alkyl ester concurrently with said retinoic acid.

5. The method of claim 1 , further comprising administering said nicotinic acid alkyl ester to said subject for at least one month prior to administration of said retinoic acid.

6. The method of claim 1 , wherein said subject is a mammal.

7. The method of claim 6 wherein said mammal is a human.

Assignments (2)
RELEASE OF SECURITY INTEREST Recorded Sep 20, 2021
From: BLUE TORCH FINANCE LLC
To: NIADYNE, INC.
Reel/Frame 057535/0177 →
ASSIGNMENT FOR SECURITY -- PATENTS Recorded Jun 17, 2019
From: NIADYNE, INC.
To: BLUE TORCH FINANCE, LLC, AS COLLATERAL AGENT
Reel/Frame 049494/0669 →